RecruitingPHASE2, PHASE3NCT07159841
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Studying Congenital adrenal hyperplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Crinetics Pharmaceuticals Inc.
- Intervention
- Atumelnant(drug)
- Enrollment
- 153 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2026 – 2030
Study locations (18)
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- Cook Children's Health Care System, Fort Worth, Texas, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
- Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- Instituto Médico Especializado (IME), Buenos Aires, Argentina
- Institute of Endocrinology of Diabetes, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
- Queensland Children's Hospital, South Brisbane, Queensland, Australia
- Monash Children's Hospital, Monash Health, Clayton, Victoria, Australia
- UZ Leuven (Universitair Ziekenhuis Leuven), Leuven, Flemish Brabant, Belgium
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo, São Paulo, Brazil
- Hopital Kremlin-Bicétre - APHP Paris Saclay, Le Kremlin-Bicêtre, France
- Hopital Robert Debre, Paris, France
- AOU Federico II, Naples, Campania, Italy
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07159841 on ClinicalTrials.govOther trials for Congenital adrenal hyperplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07144163A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaCrinetics Pharmaceuticals Inc.
- RECRUITINGPHASE2NCT07187375Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldNeurocrine Biosciences
- RECRUITINGNANCT07473804Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)IRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06712823An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894Crinetics Pharmaceuticals Inc.
- RECRUITINGNANCT07099456Fertility And Sexual Function In CAH: CALLIOPEUniversity of Roma La Sapienza
- RECRUITINGPHASE1, PHASE2NCT05669950A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaH. Lundbeck A/S
- RECRUITINGNCT06754423Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase DeficiencyIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04783181A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)Adrenas Therapeutics Inc